AppGenex Diagnostics develops and commercializes multiplex diagnostics for the detection of infectious diseases
AppGenex Diagnostics develops and commercializes multiplex diagnostics for the detection of infectious diseases
About Us
AppGenex Diagnostics is a diagnostic company focused on the development and commercialization of multiplexed products for the diagnosis of infectious diseases, with an initial emphasis on tuberculosis (TB). Our technology is instrument platform agnostic in that we leverage the right instrumentation platform for the right diagnostic application that works for our target clinical market. Our current products and product candidates are based on bead-based flow cytometric multiplex technology. This technology has the ability to simultaneously detect multiple biomolecules, for instance, patient’s antibodies against specific Mycobacterium tuberculosis antigens, in a single sample. Importantly, the multiplex technology has the flexibility to be configured for high throughput and point-of-care needs for obtaining results in an economic and rapid fashion.
AppGenex Diagnostics has a pipeline of proteomic (antigen and antibody markers of disease) and molecular (nucleic acid) TB diagnostic products that address the key clinical decision points in diagnosis, treatment selection and treatment monitoring for TB detection and disease management.
